<HashMap><database>biostudies-literature</database><scores/><additional><submitter>O'Brien CA</submitter><funding>National Institute of Neurological Disorders and Stroke</funding><funding>Children&amp;amp;apos;s Hospital of Philadelphia</funding><funding>Silicon Valley Community Foundation</funding><funding>NINDS NIH HHS</funding><funding>National Institute of Dental and Craniofacial Research</funding><funding>National Institutes of Health</funding><funding>NIH HHS</funding><pagination>6248-6264</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12444772</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>33(12)</volume><pubmed_abstract>Microglia replacement therapy, where endogenous brain macrophages are depleted and replaced by adoptively transferred surrogates, holds promise for treating pediatric neurologic diseases, but little is known about how early-life microglia replacement impacts the brain. We sought to investigate how early postnatal microglia depletion and adoptive macrophage transfer, essential components of microglia replacement, durably impact neural circuits in a mouse model. Using both pharmacologic and genetic models, postnatal microglia depletion worsened adult seizure severity, mortality, and neuropathology in a chemical seizure model. Replacement of endogenous microglia by adoptive transfer of monocytes rescued this effect, while transfer of authentic microglia from a donor mouse did not, and even wo</pubmed_abstract><journal>Molecular therapy : the journal of the American Society of Gene Therapy</journal><pubmed_title>Neonatal microglia replacement in mice modulates seizure severity in adulthood.</pubmed_title><pmcid>PMC12444772</pmcid><funding_grant_id>R21 NS135366</funding_grant_id><funding_grant_id>DP5 OD036159</funding_grant_id><funding_grant_id>DP5OD036159</funding_grant_id><funding_grant_id>R21 NS128745</funding_grant_id><funding_grant_id>T32 NS007413</funding_grant_id><funding_grant_id>R01 NS120099</funding_grant_id><funding_grant_id>2023-33184</funding_grant_id><funding_grant_id>R01 NS129737</funding_grant_id><funding_grant_id>R01 NS120960</funding_grant_id><funding_grant_id>R01-NS-120960</funding_grant_id><funding_grant_id>R01-NS-129737-01</funding_grant_id><pubmed_authors>Cohen AS</pubmed_authors><pubmed_authors>Bennett ML</pubmed_authors><pubmed_authors>Bennett FC</pubmed_authors><pubmed_authors>Shukla S</pubmed_authors><pubmed_authors>Levitt EM</pubmed_authors><pubmed_authors>Delcy SAS</pubmed_authors><pubmed_authors>O'Brien CA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Neonatal microglia replacement in mice modulates seizure severity in adulthood.</name><description>Microglia replacement therapy, where endogenous brain macrophages are depleted and replaced by adoptively transferred surrogates, holds promise for treating pediatric neurologic diseases, but little is known about how early-life microglia replacement impacts the brain. We sought to investigate how early postnatal microglia depletion and adoptive macrophage transfer, essential components of microglia replacement, durably impact neural circuits in a mouse model. Using both pharmacologic and genetic models, postnatal microglia depletion worsened adult seizure severity, mortality, and neuropathology in a chemical seizure model. Replacement of endogenous microglia by adoptive transfer of monocytes rescued this effect, while transfer of authentic microglia from a donor mouse did not, and even wo</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-07-15T07:45:38.084Z</modification><creation>2026-07-01T03:08:03.588Z</creation></dates><accession>S-EPMC12444772</accession><cross_references><pubmed>40873033</pubmed><doi>10.1016/j.ymthe.2025.08.039</doi></cross_references></HashMap>